General Announcement::GPL receives ANDA approval for Arformoterol Tartrate Inhalation Solution

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
23-Jun-2021 13:52:05
Status
New
Announcement Sub Title
GPL receives ANDA approval for Arformoterol Tartrate Inhalation Solution
Announcement Reference
SG210623OTHR0UPJ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
23/06/2021 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials

Attachments

SGX_PR 23062021.pdf
Total size =825K